AZD0780
AZD0780 (EX-A6975) is an oral small molecule PCSK9 inhibitor being developed by AstraZeneca as a first-in-class treatment for patients with dyslipidemia that is uncontrolled with statins alone.
Product Specifications
CAS Number
2455427-91-3
Stability
≥ 2 years
Purity
>98% (HPLC)
Weight
414.41
Molecular Formula
C20H20F2N6O2
Notes
Research use only, not for human use.
Receptor
Others
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6393125-01 0.1 mL
RXRA (NR2B1, Retinoic Acid Receptor RXR-alpha, Nuclear Receptor Subfamily 2 Group B Member 1, Retinoid X Receptor alpha, FLJ00280, FLJ00318, FLJ16020, FLJ16733, MGC102720) (Biotin)
Ask
View Details MBS6393125-02 5x 0.1 mL
RXRA (NR2B1, Retinoic Acid Receptor RXR-alpha, Nuclear Receptor Subfamily 2 Group B Member 1, Retinoid X Receptor alpha, FLJ00280, FLJ00318, FLJ16020, FLJ16733, MGC102720) (Biotin)
Ask
View Details 